NCT07439653PHASE1, PHASE2Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

TORL Biotherapeutics, LLC

Start Date

3/31/2026

Completion Date

9/30/2029

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections

Interventions

DRUG

TORL-5-700

DRUG

TORL-5-700 at MTD/RP2D

DRUG

TORL-5-700 at MTD/RP2D in combination with another agent

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Locations

UCLA

Santa Monica, California 90404

United States

Stanford University

Stanford, California 94305

United States

Sarah Cannon Research Institute

Nashville, Tennessee 37203

United States